Prof. Agnieszka Dobrzyn
Director of Nencki Institute of Experimental Biology PAS, Warsaw, Poland; Head of the Laboratory of Cell Signaling and Metabolic Disorders; Director of SARK-Poland (translational scientist without borders – within the framework of bilateral agreement between Nencki Institute and Stanford University); Advisory Board member of Polish Science Contact Agency (PolSCA) in Brussels, Belgium; Head of the PhD School in Natural and BioMedical Sciences in Warsaw (Warsaw4PhD) PhD in medical sciences at the Medical University of Bialystok, Poland (2001); 2002-2006 – postdoctoral training at the Department of Biochemistry, University of Wisconsin-Madison, USA; 2006 - Habilitation (DSc) in medical sciences, Poland; 2015 - Full Professor in biology - title from the President of Poland; 2022 – member of the Polish Academy of Sciences.
Research:
Professor Agnieszka Dobrzyn is an author of more than 100 research publications, three book chapters, and four patents, incl. the method for the early diagnosis of a pre-diabetic state and type 2 diabetes' (US 10222384, PCT/IB2016/051087) and flow microsystem for the creation, culture and fluorescent imaging of three-dimensional aggregates of pancreatic island cells for the treatment of type 1 diabetes (P.431667). Prof. Dobrzyn supervised ten PhD students and six postdocs. Her laboratory is focused on signaling pathways affected by lipid mediators during pancreatic organogenesis and α-β cells communication in insulin resistance and diabetes. Prof. Dobrzyn is one of the leaders of a multi-sectorial consortium generating Human Bionic Pancreas – a 3D functional scaffold for islet transplants, as a fully-fledged method for the treatment of diabetes. For her work prof. Dobrzyn received Award of the Minister of Science and Higher Education for outstanding scientific achievements, in 2016 and 2020. During pandemic COVID 19, Prof. Agnieszka Dobrzyn was the National Coordinator for mass testing for SARS-CoV-2 in Poland.